RxDoctor Payments Data

Ryan Geist

Clinton, NCNPI 1659020022

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.

$7,568in general payments, 2019–2025

Across 129 payments — averaging $58.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$920
  • Sun Pharmaceutical Industries Inc.$913
  • UCB, Inc.$913
  • Dermavant Sciences, Inc.$622
  • Novartis$564
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$7,17595%
  • Education$3935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Quetiapine Fumarate11$463

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →